Hong Kong BlueSky Technologies Innovation Co., Limited (hereinafter referred to as "BlueSky Tech") today announced that it has partnered with Osaka University in Japan to incubate a company—— Endoluminal Solutions Inc.(Endoluminal Solutions) has officially signed a "Strategic Cooperation Agreement." The two parties will jointly advance the development and application of the world's thinnest disposable endoscopy system (diameter only 4 millimeters), accelerate the construction of their AI-assisted diagnostic and screening information digital platform, and strive to set a new global standard for early gastric cancer screening.
February 10, 2026, Hong Kong
Endoluminal Solutions is developing the world's thinnest (just 4 mm diameter) disposable endoscope, specifically designed for large-scale screening of gastric cancer. Compared to traditional barium meals (which have low precision and radiation), this system significantly reduces discomfort and the risk of cross-infection; Compared to existing gastroscopes (which are costly and complex to operate), they are more economical and accessible, and are expected to become a new infrastructure for efficient group screening.
Strategic Synergy: Addressing regional health challenges through technology investment
Gastric cancer is a common cancer in East Asia. Early screening is key to reducing mortality, but existing methods face issues such as low precision, high cost, and poor accessibility. Based on deep insights into regional health needs, Lantian Technology Innovation supports Endoluminal Solutions' integrated "equipment + AI + digital platform" solution through this strategic partnership, aiming to improve screening efficiency and continuity, empowering screening institutions.
Investor Vision: Building a "Zero Stomach Cancer Deaths Society" Together”
Zhang Benyan, Director and General Manager of Lantian Tech, stated: "Stomach cancer is a major challenge that continues to affect the health of people in East Asia and around the world, urgently requiring simple, economical, and highly accurate early screening methods. Endoluminal Solutions combines these advantages, not only bridging the medical gap in Japan but also offering effective solutions for Asia and the world. Lantian Technology Innovation endorses its vision of a "zero deaths in stomach cancer," upholds the concept of "medical care knows no borders," and will fully support the product's early rollout, helping this system become the standard choice for future global gastric cancer screening.
Looking ahead
Endoluminal Solutions will accelerate the research and integration of endoscopes, AI systems, and digital platforms, planning to launch its Series A financing round between late 2026 and early 2027, and actively seek global strategic partnerships starting from Asia. As a strategic partner, Lantian Technology will continue to support its long-term development, jointly promote innovation in gastric cancer screening models, benefit more people, and contribute to improving global public health standards.